Jack A. Khattar Supernus Pharmaceuticals, Inc. (SUPN) insider trading activity

Jack A. Khattar is President, CEO of SUPERNUS PHARMACEUTICALS, INC.. Currently has a direct ownership of 1.01 Million shares of SUPN, which is worth approximately $32.6 Million. The most recent transaction as insider was on Nov 15, 2022, when has been sold 1,783 shares (Common Stock) at a price of $9.56 per share, resulting in proceeds of $17,045. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.01M

5.78% 3M change

10.21% 12M change

Total Value Held $32.6 Million

Jack A. Khattar Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 15 2022	BUY Exercise of conversion of derivative security	$17,045 $9.56 p/Share	1,783 Added 0.23%	781,857 Common Stock
Sep 14 2022	SELL Exercise of conversion of derivative security	$46,575 $33.75 p/Share	1,380 Reduced 0.18%	780,074 Common Stock
Sep 14 2022	BUY Exercise of conversion of derivative security	-	5,895 Added 0.75%	781,454 Common Stock
Aug 16 2022	SELL Exercise of conversion of derivative security	$312,280 $34.01 p/Share	9,182 Reduced 1.15%	790,249 Common Stock
Aug 16 2022	SELL Open market or private sale	$499,607 $34.01 p/Share	14,690 Reduced 1.86%	775,559 Common Stock
Aug 16 2022	BUY Exercise of conversion of derivative security	-	39,530 Added 4.71%	799,431 Common Stock
Aug 15 2022	SELL Exercise of conversion of derivative security	$367,966 $34.03 p/Share	10,813 Reduced 1.37%	777,203 Common Stock
Aug 15 2022	SELL Open market or private sale	$588,787 $34.03 p/Share	17,302 Reduced 2.23%	759,901 Common Stock
Aug 15 2022	BUY Exercise of conversion of derivative security	-	46,575 Added 5.58%	788,016 Common Stock
Aug 10 2022	SELL Open market or private sale	$887,803 $31.22 p/Share	28,437 Reduced 3.69%	741,441 Common Stock
Aug 10 2022	BUY Exercise of conversion of derivative security	-	44,900 Added 5.51%	769,878 Common Stock
Aug 09 2022	SELL Open market or private sale	$1,228,276 $31.15 p/Share	39,431 Reduced 5.16%	724,978 Common Stock
Aug 09 2022	BUY Exercise of conversion of derivative security	-	63,100 Added 7.63%	764,409 Common Stock
Aug 08 2022	SELL Open market or private sale	$3,744,726 $31.76 p/Share	117,907 Reduced 14.39%	701,309 Common Stock
Aug 08 2022	BUY Exercise of conversion of derivative security	-	192,000 Added 18.99%	819,216 Common Stock
Mar 18 2022	BUY Other acquisition or disposition	-	10,750 Added 1.69%	627,216 Common Stock
Mar 14 2022	BUY Grant, award, or other acquisition	-	60,000 Added 8.87%	616,466 Common Stock
Jul 30 2021	BUY Grant, award, or other acquisition	-	40,000 Added 6.71%	556,466 Common Stock
Mar 26 2021	BUY Other acquisition or disposition	-	10,000 Added 1.9%	516,466 Common Stock

Also insider at

SCPH

scPharmaceuticals Inc. Healthcare

CGTX

COGNITION THERAPEUTICS INC Healthcare

Director

JAK

Jack A. Khattar

President, CEO

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SUPN shares.

Notify only if

Value

Insider Trading

Get notified when an Supernus Pharmaceuticals, Inc. insider buys or sells SUPN shares.

Notify only if

Operation

Value

Type

News

Receive news related to SUPERNUS PHARMACEUTICALS, INC.

Track Activities on SUPN

Account